alunbrig
(brigatinib)Takeda Pharmaceuticals America, Inc.
Usage: ALUNBRIG is indicated for the treatment of adult patients with ALK-positive metastatic non-small cell lung cancer (NSCLC), confirmed by an FDA-approved test.
18 results
cyramza
(ramucirumab)Eli Lilly and CompanyUsage: CYRAMZA is indicated for treating advanced or metastatic gastric/gastro-esophageal junction cancer, non-small cell lung cancer (NSCLC), colorectal cancer, and hepatocellular carcinoma in specific patient populations following prior treatments with chemotherapy or targeted therapies. It can be used alone or in combination with other agents.gavreto
(Pralsetinib)Rigel Pharmaceuticals, Inc.Usage: GAVRETO is indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and for adult and pediatric patients aged 12 and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy and who are radioactive iodine-refractory.imjudo
(tremelimumab)AstraZeneca Pharmaceuticals LPUsage: IMJUDO is indicated for the treatment of adult patients with unresectable hepatocellular carcinoma in combination with durvalumab. It is also used with durvalumab and platinum-based chemotherapy for adult patients with metastatic non-small cell lung cancer who lack sensitizing EGFR mutations or ALK genomic aberrations.keytruda - pembrolizumab injection, powder, lyophilized, for solution
(Pembrolizumab)Merck Sharp & Dohme LlcUsage: KEYTRUDA is indicated for various cancers, including unresectable or metastatic melanoma, non-small cell lung cancer (NSCLC), malignant pleural mesothelioma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, and several others. It targets PD-1 to boost immune response against tumors.lazcluze
(lazertinib)Janssen Biotech, Inc.Usage: LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations (exon 19 deletions or exon 21 L858R) as determined by an FDA-approved test.mektovi
(BINIMETINIB)Array BioPharma Inc.Usage: MEKTOVI is indicated, in combination with encorafenib, for treating unresectable or metastatic melanoma and metastatic non-small cell lung cancer (NSCLC) in adult patients with BRAF V600E or V600K mutations, as identified by FDA-approved testing.paclitaxel
(Paclitaxel)Natco Pharma USA LLCUsage: Paclitaxel Injection, USP is indicated for advanced ovarian carcinoma, adjuvant treatment of node-positive breast cancer, treatment after chemotherapy failure in metastatic breast cancer, first-line therapy for non-small cell lung cancer, and second-line treatment of AIDS-related Kaposi’s sarcoma.paclitaxel
(Paclitaxel)Teva Pharmaceuticals, Inc.Usage: Paclitaxel Protein-Bound Particles for Injectable Suspension is indicated for treating metastatic breast cancer post-chemotherapy failure, first-line therapy for non-small cell lung cancer in combination with carboplatin, and first-line treatment of metastatic adenocarcinoma of the pancreas with gemcitabine.retevmo
(selpercatinib)Eli Lilly and CompanyUsage: RETEVMO is indicated for adult and pediatric patients aged 2 years and older with RET fusion-positive non-small cell lung cancer, RET-mutant advanced medullary thyroid cancer, RET fusion-positive advanced thyroid cancer, and RET fusion-positive solid tumors that require systemic therapy, following specific testing.